Effectiveness and Safety of Biosimilar Anti-Vascular Endothelial Growth Factor for Retinal Diseases: A Systematic Review and Meta-Analysis
Biosimilar anti-VEGF is comparable to reference anti-VEGF with respect to safety profile and visual outcomes. Future research should prioritize including diverse patient populations and adopting standardized, extended follow-up periods to enhance the assessment of long-term safety and effectiveness of biosimilars.
Authors
- Brian G. Ballios (ORCID: https://orcid.org/0000-0002-4644-3339)
- Ryan S. Huang (ORCID: https://orcid.org/0000-0002-3404-5376)
- Bhadra U. Pandya (ORCID: https://orcid.org/0000-0002-7646-3381)
- Andrew Mihalache;
- Tina Felfeli
- Xingshan Cao
- Aaditeya Jhaveri
Institutions
- Sunnybrook Health Science Centre (CA)
- University Health Network (CA)
- University of Toronto (CA)
- Health Sciences Centre (CA)
- Public Health Ontario (CA)
Publication Details
- Journal
- Retina
- Published
- 2026-02-11
- DOI
- https://doi.org/10.1097/iae.0000000000004807
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00